Tillner J, et al. - In healthy volunteers and in patients with overweight/obesity and type 2 diabetes, researchers assessed the safety, pharmacokinetics, and pharmacodynamics of SAR425899, a novel polypeptide active as an agonist at both the glucagon-like peptide-1 receptor (GLP-1 R) and the glucagon receptor. For this investigation, they tested subcutaneous administrations of SAR425899 in two randomized, placebo-controlled, double-blind clinical trials. Most frequently reported adverse events were gastrointestinal. In patients compared with healthy volunteers, gastrointestinal side effects were less pronounced. In patients, SAR425899 significantly reduced levels of fasting plasma glucose and glycated haemoglobin. In both healthy volunteers and patients, SAR425899 was well tolerated and led to favourable glycaemic effects in patients with type 2 diabetes and weight reduction.